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A B S T R A C T
Background
Given the relatively high prevalence of age-related macular degeneration (AMD) and the increased incidence of AMD as populations
age, the results of trials of novel treatments are awaited with much anticipation. The complement cascade describes a series of proteolytic
reactions occurring throughout the body that generate proteins with a variety of roles including the initiation and promotion of immune
reactions against foreign materials or micro-organisms. The complement cascade is normally tightly regulated, but much evidence
implicates complement overactivity in AMD and so it is a logical therapeutic target in the treatment of AMD.
Objectives
To assess the effects and safety of complement inhibitors in the prevention or treatment of advanced AMD.
Search methods
We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2013, Issue 11),
Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE
(January 1946 to November 2013), EMBASE (January 1980 to November 2013), Allied and Complementary Medicine Database
(AMED) (January 1985 toNovember 2013), Latin American and Caribbean Literature on Health Sciences (LILACS) (January 1982 to
November 2013), OpenGrey (System for Information on Grey Literature in Europe) (www.opengrey.eu/), Web of Science Conference
Proceedings Citation Index - Science (CPCI-S) (January 1990 to November 2013), the metaRegister of Controlled Trials (mRCT) (
www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform
(ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last
searched the electronic databases on 21 November 2013. We also performed handsearching of proceedings, from 2012 onwards, of
meetings and conferences of specific professional organisations.
Selection criteria
We planned to include randomised controlled trials (RCTs) with parallel treatment groups which investigated either the prevention or
treatment of advanced AMD by inhibition of the complement cascade.
Data collection and analysis
Two authors (MW and GMcK) independently evaluated all the titles and abstracts resulting from the searches.We contacted companies
running clinical trials which had not yet reported results to request information. Since no trials met our inclusion criteria, we undertook
no assessment of quality or meta-analysis.
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Main results
We identified and screened 317 references but there were no published RCTs that met the inclusion criteria. We identified two ongoing
studies: one phase I study and one phase II study.
Authors’ conclusions
There is insufficient information at present to generate evidence-based recommendations on the potential safety and efficacy of
complement inhibitors for prevention or treatment of AMD. However we anticipate the results of ongoing trials.
P L A I N L A N G U A G E S U M M A R Y
Complement inhibitors for age-related macular degeneration
Advanced age-related macular degeneration (AMD) is an eye condition which principally affects the over 65s. In this age group it is
the most common cause of loss of vision in the developed world, and the third most common cause globally. AMD causes loss of
central vision. Despite advances in the understanding of AMD and the recent introduction of new treatments for some forms of AMD,
the visual loss it causes is irreversible in most cases. When it affects both eyes, the impact on day to day functioning is huge. As the
proportion of older people increases, larger numbers of people are likely to be affected by AMD in the future.
The complement cascade is the name for a series of proteins which form part of the body’s immune system, helping to fight infection.
The complement system is constantly active at a low level, and is tightly regulated. However evidence suggests that complement cascade
overactivity may play a role in AMD, and so it is logical that drugs which inhibit the cascade may have a role in the treatment of AMD.
This review sought to identify trials investigating the potential benefits and safety of complement inhibitors for AMD. No relevant
trials have been completed but we anticipate that updates of this review will in future have results to analyse. There is insufficient
information at present to generate evidence-based recommendations on the potential safety and efficacy of complement inhibitors for
prevention or treatment of AMD.
B A C K G R O U N D
Advanced age-related macular degeneration (AMD) is the most
common cause of blindness in those aged over 65 years in the
developed world and the third most common cause globally (
Augood 2006). In Great Britain (England, Wales and Scotland) it
is estimated that AMD is the cause of vision impairment in 3.7%
(95% confidence interval 3.2% to 4.2%) of the population over
75 years of age (Evans 2004). Given the relatively high prevalence
of AMD and the increased incidence of AMD as populations
age, the results of trials of novel treatments such as complement
inhibitors are awaitedwithmuch anticipation. Patients, physicians
and funders of health care require access to a critical evaluation of
the evidence base on which to base treatment decisions.
Description of the condition
Age-related changes that occur in the macula as a matter of age
include the appearance of drusen. These are focal extracellular
deposits between the retina and the retinal pigment epithelium
(RPE), visible ophthalmoscopically as yellow dots. Drusen, pig-
ment abnormalities and patchy atrophy of the RPE are a cluster
of signs which constitute early AMD. While early AMD does not
have an impact on central visual function, these signs may herald
progression to advanced AMD (Hogg 2007). This involves geo-
graphic atrophy (or atrophic AMD), which is confluent atrophy
with loss of the RPE and the choriocapillaris or neovascular AMD,
which is an acute exudative pathology that affects the central mac-
ular tissues. This latter form of AMD is due to the onset of neovas-
cularisation arising in the choroid or de novo in the retina. It can
be classified on the basis of indocyanine green angiography and
fluorescein angiography into polypoidal choroidopathy, choroidal
neovascularisation and retinal angiomatous proliferation. These
abnormal vascular complexes leak serous fluid, are unstable and
rupture, which leads to frank haemorrhage. Eventually they form
fibrous scars that destroy the architecture of the choroid, RPE and
retina tissue. Population-based studies show that, in cases of late
AMD, neovascular forms are more common than geographic at-
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rophy (Owen 2003).
Patients with neovascular AMD typically present with acute onset
of visual symptoms such as difficulty reading, particularly small
print, distortion, waviness of straight lines or in some cases a total
loss of central vision. Sometimes patients are not aware of uni-
lateral AMD, particularly when the fellow eye has normal vision.
However, once a patient has lost central vision in one eye, the onset
of symptoms in the fellow eye is invariably noticed immediately.
Clinical examination by an ophthalmologist consists of functional
andmorphological assessments. The latter typically include colour
fundus photography, fluorescein angiography, indocyanine green
angiography and ocular coherence tomography (OCT). The im-
provements in quality and resolution of OCT scanning combined
with its non-invasive nature have led to its widespread use as a
primary method for diagnosis and monitoring of responsiveness
to treatments.
The effect of advanced AMD on central vision is often devastat-
ing. There are no effective treatments to restore vision following
the confluent cell loss of the atrophic variety. The introduction
of biologicals which inhibit vascular endothelial cell growth fac-
tor (VEGF) in the management of neovascular AMD has led to
improved outcomes in recent times. Despite this, most patients
do not recover lost vision. Not only is the advanced form of the
disease common, but when one eye is affected by advanced AMD,
the risk of progression to late-stage disease in the fellow eye rises to
45% over a five-year period (AREDS 2001). Bilateral late AMD
impairs central vision and has a huge impact on visual function-
ing, and thus the handicap is great.
The risk of having both early and late AMD is strongly related
to age. Pooled population-based studies of predominately white
populations from different continents have revealed estimates of
a prevalence of advanced AMD of 3.32% of those over 65 years
and approximately 11% of over 90s (Owen 2003). Given that
current trends in the developed world predict an ageing popula-
tion, the burden of AMD on populations and public interest in
its causes and potential cures will increase. A recent systematic re-
view (Chakravarthy 2010) has confirmed the importance of previ-
ously identified risk factors which include family history (Seddon
1997), smoking, cardiovascular disease, poor diet and nutrition,
hypertension and obesity. There appears to be a dose-response re-
lationship between smoking and risk of AMD (Thornton 2005).
Most of the risk that a family history poses has a genetic basis.
Several genes have been associated with AMD (Patel 2008). In
2005 the results of four studies were published which each in-
dependently identified an association between a specific genetic
change and the disease (Edwards 2005; Hageman 2005; Haines
2005; Klein 2005). The change was a single nucleotide polymor-
phism in amino acid 402 (Y402H) of the gene for a key regulator
of the complement cascade, complement factor H (CFH). Since
then another study has replicated the findings (Despriet 2006),
and there has been great interest in polymorphisms in other genes
which code for proteins involved in the complement cascade and
whichmay have a role in the pathogenesis of AMD (Haines 2007).
The complement cascade describes a pathway which, when ac-
tivated, results in the sequential proteolytic cleavage of a series
of proteins, termed C1 to C9. Components of complement are
distributed throughout the body, ready to engage in a variety of
roles. These include initiating and promoting immune reactions
against foreign materials or micro-organisms, clearing apoptotic
debris in utero or during the development of neuroplasticity and
facilitating the clearance of necrotic debris.
Much evidence, other than the genetic associations, also impli-
cates excessive complement activity in causing AMD (Sivaprasad
2006). For example, components such as C5 (Hageman 2001),
inhibitors such as complement factor H (Hageman 2005), regu-
lators such as vitronectin (Crabb 2002) and potential activators
such as beta-amyloid (Johnson 2002) of the complement cascade
have been identified in drusen and in the retina-choroid complex
of eyes with AMD. Messenger ribonucleic acid (mRNA) for a
complement component has been detected in RPE cells, suggest-
ing that this component is produced locally in the retina (Johnson
2000). Animal models suggest that the complement cascade has
a major contributory role in laser-induced choroidal neovascular-
isation, possibly through the stimulation of increased levels of an-
giogenic growth factors (Bora 2005). Such insights into possible
aetiologies have led to attempts to develop and apply therapeutic
interventions that inhibit complement.
Description of the intervention
The complement cascade consists of a series of steps, from ini-
tial activation to production of terminal components. Any stage
therefore is, in theory, a potential target for inhibition. Comple-
ment cascade inhibition as a therapeutic intervention for AMD is
a novel concept, and there are challenges to overcome in the de-
velopment of any novel therapeutic agent. It must be understood,
for example, that preventing one step of the cascade could in fact
stop the formation of all downstream products. Agents designed
to inhibit the complement cascade must effectively dampen hy-
peractivity without compromising the ability to perform its nor-
mal functions. To understand how a complement inhibitor might
work, an overview of complement is necessary.
Three pathways of complement activation exist (Markiewski 2007;
Ricklin 2007; Rodriguez 2004). They converge on the activation
by cleavage of C3, reaching that step in different ways. The clas-
sic pathway is initiated by the component C1q interacting either
with immune complexes or non-immune complexes such as C-re-
active protein or fibrillar beta-amyloid (Heneka 2007). The lectin
pathway is activated by recognition and binding of densely ar-
ranged mannose on bacterial surfaces by mannose-binding lectin
proteins. The result of either classic or lectin pathway activation
is cleavage of C4 by a serine protease to C4a and C4b. C2 then
binds to C4b. The result of further protease activity is the gen-
eration of C4bC2a which acts as C3 convertase. The alternative
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pathway describes the hydrolysis of C3 to C3w: the resultant con-
formational change allows binding of factor B to C3w, and the
complex acts as an alternative C3 convertase. The hydrolysis can
be activated by foreign pathogens, cellular debris such as apop-
totic bodies or by macromolecular complexes such as lipofuscin
or amyloid-beta aggregates. However, as C3 also hydrolyses spon-
taneously, the alternative pathway allows a continuous low level
of activity of complement. This pathway results in the deposition
of C3b on foreign or abnormal surfaces. Once complement is ac-
tivated, a series of proteolytic reactions ensues, producing a suc-
cession of complement proteins. C3 is cleaved to form C3a and
C3b. C3b plays a central role in several ways. It covalently binds
to pathogen surfaces: this is opsonisation and facilitates phagocy-
tosis. Surface-bound C3b combines with factor B, and cleavage by
factor D leads to C3bBb: a C3 convertase. Thus amplification of
complement activation occurs. C5 convertase results either from
combination of two surface-bound C3b molecules and factor B or
from an assembly of C4b, C2a and C3b. C3a, C4a and C5a which
are potent chemo-attractants for phagocytes. As the cascade con-
tinues, conversion occurs of C5 to products (C6, C7, C8 and C9)
which eventually assemble as amembrane attack complex (MAC).
MACs insert into cellular plasmamembranes and if enoughMACs
attack a cell, it can lyse. A full understanding of the complement
cascade, however, is lacking. Some evidence is emerging that it can
be activated in other ways, perhaps, for example, by interaction
with the coagulation cascade.
A balance exists between permitting and dampening complement
activity. Given the constitutive nature of the alternative path-
way, tight regulation of the cascade is essential. Control is partly
achieved by C3 convertase and C3b having short half-lives. C3b
that is deposited on foreign cells is stabilised by the protein prop-
erdin. However, C3b attached to host cell surfaces is degraded by
a number of regulators, both surface-bound and soluble. These
include complement factor H (CFH), decay-accelerating factor
(CD55), membrane cofactor protein (CD46) and complement
receptor 1 (CD35). The formation of the MAC is prevented by
another regulator, namely CD59.
In animal models, the lack of CFH results in uncontrolled alter-
native pathway complement activation (Rodriguez 2004). CFH
reins in complement in two ways. Firstly, it accelerates the decay
of C3 and C3b convertases and, secondly, it is a cofactor for com-
plement factor I (CFI). CFI degrades soluble and surface-bound
C3b to an inactive form. The interaction of CFH with bound
C3b depends on the simultaneous presence of negatively charged
molecules, such as sialic acid and heparin, also bound to cell sur-
faces or extracellular matrix. It is the degree of affinity between
C3b and CFH which determines CFH’s ability to inactivate C3b,
and thus binding with these cell surface polyanions is crucial. As
amino acid 402 of CFH, the position of the single nucleotide
polymorphism most strongly associated with AMD, is located in
a region of CFH which binds heparin, the Y402H change may
impair the binding efficiency or some other aspect of the function
of the molecule and hence reduce its inhibitory abilities.
Whatever stage of the complement cascade is targeted, the active
agent could be delivered to the eye by several means: topically,
intravitreally or systemically. Similarly, the potential vehicles for
delivery of the active agent to its intended site of action in the
retina are in theory legion. As this avenue of treatment is nascent, it
is difficult to discuss complement inhibition for AMD in anything
other than general terms.
How the intervention might work
Several potential classes of complement inhibitors acting as thera-
peutic agents exist: protease inhibitors, natural complement regu-
lators, antibodies against specific complement components, func-
tional complement component inhibitors and anaphylatoxin re-
ceptor antagonists (Ricklin 2007).
Eculizumab, for example, a monoclonal antibody against C5,
prevents C5’s cleavage to C5a and C5b. It is licensed for
the treatment of paroxysmal nocturnal haemoglobinuria. The
pathogenesis of this disorder is increased MAC formation on
erythrocyte and platelet surfaces. Eculizumab may have po-
tential for the treatment of atrophic AMD, and a phase II
clinical trial on intravenous eculizumab is recruiting (Clini-
calTrials.gov identifier: NCT00935883) (Alexion Pharmaceuti-
cals: www.alexionpharm.com/). TT30, a CFH-recombinant fu-
sion protein which inhibits the alternative complement pathway
and TA106, an antibody directed against factor B, are in the
pipeline as potential treatment for AMD (Alexion Pharmaceu-
ticals: www.alexionpharm.com/). Functional complement com-
ponent inhibitors include compstatin, a peptide which blocks
the cleavage of C3 to its active products. Although the exact
mechanism of its action is unclear, it is said to be a promis-
ing drug candidate given its small size and high efficacy. An
analogue of compstatin, POT-4, has been investigated in phase
I clinical trials (ClinicalTrials.gov identifier: NCT00473928) as
a potential intravitreal agent for AMD (Potentia Pharmaceu-
ticals: www.potentiapharma.com/). Through the use of Macu-
gen, ophthalmologists are familiar with the concept of ap-
tamers. ARC1905 is an aptamer which prevents the cleavage
of C5 and may form the basis of future treatments for neo-
vascular or atrophic AMD. Phase I clinical trials are ongoing
under Archimex (ClinicalTrials.gov identifier: NCT00709527)
(www.archemix.com/website/index.php) and Ophthotech (Clin-
icalTrials.gov identifiers: NCT00950638 and NCT00709527)
(www.ophthotech.com/). Much of the pro-inflammatory effects
of complement are mediated through the anaphylatoxins C3a and
C5a. C5a receptors are found on a variety of cells, including in-
flammatory cells such as neutrophils and macrophages. JPE1375
is a C5a receptor antagonist that has undergone preclinical trials
and may have efficacy in the prevention of atrophic AMD (Jerini
AG: www.jerini.com/cms/en/home.php). Botany may also offer
treatments: a transgenic moss has been used to produce human
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CFH, with a signal peptide resulting in localisation of the recom-
binant CFH to culture supernatant (Büttner-Mainik 2011).
Why it is important to do this review
As far as the authors are aware, no phase III trials on complement
inhibitors for either the treatment of advanced AMD or its pre-
vention have reported results at the time of writing this review.
However, several complement inhibitors are in development and
appear to have promise in the prevention or treatment of AMD.
We developed the protocol for this review in anticipation of the
progress of phase III controlled clinical trials. We have no ex-
pectations about the potential efficacy or safety of complement
inhibitors, but given the wide interest in AMD, we consider it
worthwhile to have the means in place to summarise evidence as
it appears on this new class of potentially therapeutic agents. The
review is necessarily widely inclusive of different classes of comple-
ment inhibitors, different clinical endpoints and different types of
AMD. As the usefulness or otherwise of complement inhibitors
becomes clear, we may refine the review to focus on individual
drug classes, dosage variations, clinical endpoints and AMD types
which are of most interest.
O B J E C T I V E S
The aim of this review was to assess the effects and safety of com-
plement inhibitors in the prevention or treatment of advanced
age-related macular degeneration (AMD). Specifically, we sought
to clarify the direction of any effect, the size of any effect, the
consistency of any effects across studies and assess the strength of
available evidence.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We planned to include randomised controlled trials (RCTs) with
parallel treatment groups. We planned not to include other trial
designs such as cross-over or cluster designs.
Types of participants
We planned to include two types of trials. Firstly, we planned to
include trials with participants with advanced AMD which exam-
ined the treatment of advanced AMD in the treatment and con-
trol arms. We anticipate most RCTs on the use of complement
inhibitors in AMD will be in this category. Secondly, we planned
to include trials with participants who have non-advanced AMD
which looked at the prevention of advanced AMD in the treat-
ment and control arms. The nomenclaturemay vary between stud-
ies, but for this review advanced AMD was defined as geographic
atrophy involving the fovea or neovascular AMD that could be
extrafoveal, juxtafoveal or subfoveal, as identified by clinical ex-
amination, angiography, OCT or other validated criteria. We ex-
cluded causes of neovascularisation other than AMD. We defined
non-advanced AMD as early age-related maculopathy or drusen
abnormalities, pigmentary abnormalities or both without neovas-
cularisation or central geographic atrophy.We excluded studies on
the normal healthy population. There were no age, sex or ethnic
restrictions on study participants.
Types of interventions
Weplanned to include studies which compared therapeutic agents
designed to treat or prevent advanced AMD by inhibition of the
complement cascade to an active treatment, sham treatment or no
treatment.
The agents under investigation may be locally or systemically ap-
plied and may inhibit any stage of the complement cascade by any
means. We refer to these agents as complement inhibitors. There
were no restrictions regarding delivery, dose, duration or co-inter-
ventions.
Types of outcome measures
Primary outcomes
The primary outcomes for this review were as follows:
1. Loss of 15 letters or more of best corrected visual acuity
(BCVA) at one year or more follow-up, measured using charts
adhering to Bailie-Lovie principles. We converted BCVA data
derived from other types of charts to equivalent log Mean Angle
of Resolution (logMAR) units.
2. Change in BCVA after one year or more follow-up,
measured using charts adhering to Bailie-Lovie principles, with
BCVA considered as a continuous variable, either as number of
letters or logMAR units.
The rationale for one year as a time point for outcomes is that re-
cent clinical trials investigating interventions for AMD have con-
sistently presented results at one year. One year is considered to
be clinically meaningful.
Secondary outcomes
We considered the following secondary outcomes, each measured
at one year or more follow-up:
1. For those trials examining prevention of progression of non-
advanced to advanced AMD: development of advanced AMD.
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2. Maintenance of BCVA; gain in 15 or more Early Treatment
Diabetic Retinopathy Study (ETDRS) letters; loss of 30 or more
ETDRS letters and blindness, defined as visual acuity worse than
20/200.
3. Contrast sensitivity, reading speed or any other validated
measure of visual function.
4. Any quantitative measure of retinal morphology, such as
thickness or lesion size, measured by ocular coherence
tomography (OCT), fluorescein angiography or indocyanine
green angiography.
5. Adverse outcomes, specifically hypersensitive reactions,
complications of intravitreal injection (uveitis, infectious
endophthalmitis, retinal detachment) or other adverse events as
they emerged.
6. Quality of life, assessed using any validated measures.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) (which contains the Cochrane Eyes and Vi-
sion Group Trials Register) 2013, Issue 11, part of The Cochrane
Library. www.thecochranelibrary.com (accessed 21 November
2013), Ovid MEDLINE, Ovid MEDLINE In-Process and
Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid
OLDMEDLINE (January 1946 to November 2013), EMBASE
(January 1980 to November 2013), Allied and Complemen-
tary Medicine Database (AMED) (January 1985 to Novem-
ber 2013), Latin American and Caribbean Literature on Health
Sciences (LILACS) (January 1982 to November 2013), Open-
Grey (System for Information on Grey Literature in Europe) (
www.opengrey.eu/),Web of ScienceConference ProceedingsCita-
tion Index- Science (CPCI-S) (January 1990 to November 2013),
the metaRegister of Controlled Trials (mRCT) (www.controlled-
trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the
WHO International Clinical Trials Registry Platform (ICTRP) (
www.who.int/ictrp/search/en). We did not use any date or lan-
guage restrictions in the electronic searches for trials. We last
searched the electronic databases on 21 November 2013.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1), MEDLINE (Appendix 2), EMBASE (Appendix
3), AMED (Appendix 4), LILACS (Appendix 5), OpenGrey
(Appendix 6), CPCI-S (Appendix 7), mRCT (Appendix 8), Clin-
icalTrials.gov (Appendix 9) and the ICTRP (Appendix 10).
Searching other resources
We searched the Science Citation Index. We contacted compa-
nies known to be conducting any stage of trials of complement
inhibitors for AMDor having complement inhibitors for AMD in
their pipeline and requested information on any ongoing or com-
pleted trials we may not have identified in the electronic search.
Wehandsearched abstracts from the followingorganisations’meet-
ings and conferences from 2012 onwards:
• the Association for Research in Vision and Ophthalmology;
• the American Academy of Ophthalmology;
• the UK Royal College of Ophthalmologists Annual
Congress;
• the Macula Society and the Retina Society.
Data collection and analysis
Selection of studies
Two review authors (MW and GMcK) independently evaluated
all the titles and abstracts resulting from the searches.We obtained
full copies of all the reports that definitely or potentially met the
criteria for consideration in this review according to each review
author’s independent assessment. We discussed these reports and
thus compiled a definitive list of selected studies.
As we did not find any completed RCTs that could be included in
the review, we plan to follow themethods below in future updates.
Data extraction and management
Two review authors will independently extract data on all selected
studies using specially developed paper forms available from the
editorial base.Wewill compare results and resolve discrepancies by
discussion between all three authors. When data are not available
in the published report on the primary or secondary outcomes of
interest to this review, we will contact the study authors and ask
for relevant data in an effort to overcome any selective reporting
biases. When necessary, we will extract data from figures in the
reports and contact the authors to confirm or refute the accuracy
of data so obtained.
Assessment of risk of bias in included studies
We will use Chapter 8 of theCochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011) to guide the assessment
of the methodological quality of each trial included in the review.
Consequently each of two review authors (MW and GMcK) will
consider the following for each trial.
1. selection bias (as addressed by sequence generation and
allocation concealment);
2. performance bias (as addressed by masking of participants
and personnel);
3. detection bias (as addressed by masking of outcome
assessors);
4. attrition bias (as addressed by completeness of outcome
data and documentation of exclusions);
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5. reporting bias; and
6. other bias.
We will assess outcomes for each trial as ’low risk of bias’, ’high
risk of bias’ or ’unclear’. We will make such assessments using the
interpretations set out in tables 8.5a, 8.5c and 8.7a in Chapter 8
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). We will contact the authors of trials in which
outcomes are categorised as unclear for additional information.
Bias may vary between different outcomes within the same study,
for example for some outcomes, assessors and participants may be
more easily masked (e.g. grade of AMD on retinal photographs)
than for others (e.g. visual acuity). Therefore we will comment on
bias at the level of outcomes rather than the study. If other types
of bias are detected, they will be presented.
Wewill not include in themeta-analysis data on a specific outcome
from an individual trial if the outcome has an unclear or high risk
of bias in that trial. Having made these assessments independently,
the authors will discuss outcomes for each trial to agree on its bias
level and whether to include the data.We will perform a sensitivity
analysis for each outcome classed for any trial as ’high risk of bias’
or ’unclear risk of bias’ to determine whether the inclusion of all
trials’ data for that outcome would affect the conclusions. We will
present all judgements and steps relating to bias in the text.
Measures of treatment effect
Primary outcomes for this review will be i) loss of 15 or more
letters of BCVA in the treated eye and ii) change in BCVA as a
continuous variable. We will therefore calculate the following for
each trial for one year or more of follow-up: i) risk ratio (RR) of
loss of 15 ormore ETDRS letters of BCVA, ii) themean difference
(MD) of BCVA (expressed as number of letters or as logMAR)
between baseline and follow-up, as described in Chapter 9 of the
Cochrane Handbook for Systematic Reviews of Interventions (Deeks
2011).
Thus, we will consider BCVA as both a dichotomous and contin-
uous outcome. For data pertaining to dichotomous outcomes, we
will calculate RRs as this meets best the criteria set out in Chapter
9 of the Cochrane Handbook for Systematic Reviews of Interventions
(Deeks 2011).
We will summarise secondary outcomes as continuous data and
calculateMDs. We will allow for two exceptions which we consid-
ered as dichotomous, and therefore calculate an RR: i) the risk of
adverse events and ii) secondary outcomes relating to visual acuity,
i.e. the risk of maintenance of BCVA; the risk of gain in 15 or
more ETDRS letters; the risk of loss of 30 or more ETDRS letters
and the risk of blindness (visual acuity worse than 20/200). If the
scale used to measure secondary outcomes varies between studies
for any continuous outcome, such as retinal thickness, then we
will calculate standardised mean difference.
We will perform statistical analyses using The Cochrane Collab-
oration’s Review Manager (RevMan) software (Review Manager
2012).We will seek the advice of a statistician on how to deal with
multiplicity issues, as well as other issues as necessary, for example
if it is suspected that continuous data may have been skewed.
Unit of analysis issues
It is likely that randomisation will occur at the level of individuals
as treatment given to one eye, or given systemically, potentially
affects both eyes. The individual will therefore be our unit of
analysis. If both eyes are treated, then we will seek advice as to
whether to analyse the better visual acuity, the worse visual acuity
or an average.
Trialsmay compare outcomes between each individual’s treated eye
and their fellow eye. If such paired study designs are encountered,
we will seek statistical advice. It may be possible, for example, to
combine paired and unpaired trial results using the generic inverse
variance method.
Dealing with missing data
We will conduct a sensitivity analysis to examine any systematic
bias caused by exclusion of participants after randomisation, in-
cluding those lost to follow-up. We will do this by analysing the
following outcomes looking at two scenarios: i) the worst case sce-
nario, i.e. assuming either that participants lost to follow-up lost
15 or more letters visual acuity or that they all developed advanced
AMD and ii) the best case scenario, i.e. either that none of those
lost to follow-up lost 15 or more letters visual acuity at one year
follow-up or that none developed advanced AMD.
Assessment of heterogeneity
We will calculate an I2 statistic. We will also assess heterogeneity
using a Chi2 test. Given the low numbers of studies anticipated
for the initial reviews, we will use a P value of 0.1 to address the
null hypothesis of no significant heterogeneity. We will also assess
methodological variability by careful review of manuscripts.
Assessment of reporting biases
We will present a funnel plot for each outcome of five or more
study results included in the meta-analysis. We chose the num-
ber five arbitrarily. We will plot effect size on the horizontal axis
and standard error of each trial on the vertical axis. We will judge
funnel plot asymmetry by visual inspection. We will try to judge
whether asymmetry is due to publication bias or due to the ten-
dency of smaller studies to produce different effect sizes for various
reasons as outlined in Chapter 10 of the Cochrane Handbook for
Systematic Reviews of Interventions (Sterne 2011). We will present
a full description of funnel plot interpretation with the cautionary
note that such interpretation will be subjective and probably spec-
ulative. For any funnel plot which either author thinks is asym-
metrical and for which 10 or more trials are included, we will seek
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statistical advice as to whether and how to formally test for funnel
plot asymmetry.
Searching as comprehensively as possible will be the main means
of avoiding reporting biases for studies.
It is possible that trials may report only their most statistically sig-
nificant measure of visual improvement. We will overcome such
selective outcome reporting by stating the precise outcome mea-
sures a priori as above. We will present a review outcome matrix
as described in the Outcome Reporting Bias In Trials (ORBIT)
study (Kirkham 2010). We will use this review outcome matrix
to summarise, for each outcome and each trial, whether the out-
come was reported, partially reported (selectively or incompletely)
or not reported. If we believe that the outcome may have been
recorded or analysed (or both) but not reported, we will contact
the authors to ask for the relevant outcome data.
Data synthesis
We will perform meta-analysis if possible. Meta-analysis as de-
scribed in Chapter 9 of the Cochrane Handbook for Systematic Re-
views of Interventions (Deeks 2011) may not be appropriate, how-
ever in such circumstances we will give a structured summary. We
will calculate weighted averages as follows: i) RR of loss of 15
or more ETDRS letters of BCVA, ii) the MD of BCVA and iii)
when appropriate (for preventative trials), the RR of developing
advanced AMD. From the weighted averages we will derive con-
fidence intervals, a P value and number needed to treat.
If there is no evidence of significant heterogeneity between study
estimates, we will use two approaches. For both the dichotomous
and continuous data, we will use a fixed-effect model: for dichoto-
mous data we will apply the Mantel-Haenszel method, and for
continuous data we will use the inverse variance as the default ap-
proaches of RevMan. Where there are more than three studies, we
will use a random-effects model. In the absence of heterogeneity,
these should give the same results. We will compare the results
obtained using the two models. We will take care to interpret the
results of the fixed and random-effects models appropriately (Riley
2011).
If heterogeneity is found, we will use a random-effects model (the
inverse variance method as the default approach of RevMan). If we
consider the heterogeneity to be substantial, we will give a narrative
summary. We will record the Chi2 test results and the cut-off I2
statistic (Higgins 2003) for defining heterogeneity as substantial.
We will present a forest plot to allow visual assessment of overlap
between confidence intervals of studies.
Subgroup analysis and investigation of heterogeneity
We anticipated that several characteristics may emerge as poten-
tial causes of heterogeneity, representing potential modifiers of
the effectiveness of complement inhibitors. If other characteristics
emerge, they may be the basis for post hoc subgroup analysis if
authors judge them to be of major importance and if this judge-
ment is supported by external evidence.
We will perform subgroup analysis for each of the primary out-
comes of different classes of complement inhibitors. We will
adopt the definition of classes of complement inhibitors as de-
fined by Ricklin et al, as described above (Ricklin 2007): i) pro-
tease inhibitors; ii) natural complement regulators; iii) antibiotics
against specific complement components; iv) functional comple-
ment component inhibitors and v) anaphylatoxin receptor antag-
onists. Future reviews may focus entirely on one class of com-
plement inhibitor and dosage variations within that group if one
emerges as a leader in the field.
We will perform subgroup analysis for each of the primary out-
comes according to the type of advanced AMD: neovascular or
atrophic.
For the data on treatment of neovascular AMD, we will define and
analyse subgroups according to the sub-type of neovascularisation,
guided by the definitions adopted in the included trials.
We will also perform subgroup analysis based on reported ethnic-
ity.
We will use fixed-effect analyses based on the inverse variance
method if there are fewer than 10 studies available for the charac-
teristic. Otherwise we will use meta-regression. We will be mind-
ful, however, of the dangers of spurious associations derived from
subgroup analyses due to small numbers of studies or too many
comparisons.
Sensitivity analysis
We will perform sensitivity analyses: i) for each outcome to deter-
mine whether the inclusion of all outcomes classed as ’high risk
of bias’ or ’unclear risk of bias’ would affect the conclusions, and
to assess the effect of excluding all of the following trials: ii) un-
published data and iii) industry-funded studies. If the only data
available are unpublished or industry-funded, we will not perform
sensitivity analyses.
R E S U L T S
Description of studies
Results of the search
The electronic searches yielded a total of 560 references (Figure 1).
After removing duplicates we screened 402 references to identify
potentially relevant studies but found no studies that met the in-
clusion criteria. We found two ongoing trials which may be eligi-
ble for inclusion in the review (NCT00935883: NCT00950638)
and we will assess these studies when data become available. One
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trial was a phase II study on eculizumab for the treatment of non-
exudative macular degeneration (NCT00935883) for which the
final data collection date will be June 2012: the results of this study
are not yet available. The other is a phase I study, NCT00950638,
investigatingARC1905with a final data collection date of Septem-
ber 2012.
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Figure 1. Results from searching for studies for inclusion in the review.
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Included studies
No studies were eligible for potential inclusion in this review.
Excluded studies
No studies were eligible for potential inclusion in this review.
Risk of bias in included studies
We did not assess for risk of bias as no studies were included.
Effects of interventions
There were no data on which to perform meta-analysis.
D I S C U S S I O N
Examples of relevant phase I and II trials include the following
two. ’Safety of intravitreal POT-4 therapy for patients with neo-
vascular AMD (ASap)’ (NCT00473928) was a phase I, single
group assignment study primarily investigating safety, with the
secondary aims of further characterising the efficacy of POT-4 as
assessed by changes in visual acuity, retinal thickness and choroidal
neovascularisation lesion size. Data were presented at the Amer-
ican Academy of Ophthalmology (AAO) 2008 Annual Meeting
(RET03 Section II: AMD Part II, Friday Nov 7, 9:01AM). The
drug showed good tolerability and no drug-related side effects
(Anonymous 2009). The Potentia website states: “Interim results
of this trial revealed no drug-related toxicity based on clinical signs,
ophthalmic examinations, or laboratory results at any time point
monitored in patients treated with up to 150 ug/dose of POT-4.
Additionally, no serious adverse events and no identifiable intraoc-
ular inflammation were reported” (www.potentiapharma.com/).
Potentia Pharmaceuticals entered into licensing and purchase op-
tion agreements regarding the drug with Alcon in 2009. The final
data collection date for ASap was February 2010 and the study
is now complete. New analogues of compstatin are under de-
velopment (Tamamis 2012) and Anosos Biotherapeutics, a com-
pany linked with the University of Pennsylvania ’UPstart’ pro-
gramme (www.ctt.upenn.edu/upstart.html) is developing related
compounds with greater potency for AMD.
’ARC1905 (ANTI-C5 APTAMER) given either in combination
therapy with Lucentis® 0.5 mg/eye in subjects with neovascu-
lar AMD’ (NCT00709527) was a non-randomised, open-label,
phase I, dose-escalating, prospective study investigating intravit-
real ARC1905 in combination with ranibizumab for neovascular
AMD. The final data collection date was March 2011. Data were
reported at the Association for Research in Vision and Ophthal-
mology (ARVO) 2010 meeting. Fifty-eight participants were ini-
tiated in to the study and 48 had received at least two doses of
the experimental regimen. There was no evidence of dose-limiting
toxicity and 35% of participants experienced a gain in 3 or more
ETDRS lines of BCVA.
Such phase I and II trials may provide an impetus for phase III
trials and eventually for the use of complement inhibitors in prac-
tice. We hope that in updates of this review we will have trials
on which to perform meta-analysis. Having the protocol for this
review published in advance of such data will allow a systematic
review and meta-analysis to proceed without delay at the update
stage, and also highlights an area of growing interest.
The two ongoing studies mentioned above are described in
Characteristics of ongoing studies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is insufficient information at present to generate evidence-
based recommendations on the potential safety and efficacy of
complement inhibitors for prevention or treatment of AMD.
However we anticipate the results of two trials: one phase I and
one phase II trial, presently ongoing.
Implications for research
The treatment of AMD has been revolutionised by the advent
of VEGF-antagonists. There are a multitude of other potential
treatments currently under investigation. In time these, along
with knowledge of a patient’s relevant genetic make-up (Schwartz
2011), may allow individualised treatment. Preclinical evidence
implicating complement overactivity in the pathogenesis of AMD
suggests that inhibition of pathways leading to complement acti-
vation may in the future have a prominent role in treatment of
AMD, although there are challenges to overcome first (Issa 2011;
Khandhadia 2012; Troutbeck 2012). Phase III studies investigat-
ing the safety and efficacy of complement inhibitors for AMD in
comparison to existing treatments are anticpated with interest.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of ongoing studies [ordered by study ID]
NCT00935883
Trial name or title ’Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration’
(COMPLETE)
Methods Randomised, double-arm, double-masked, phase II trial
Participants Over 50 years with nonexudative AMD and no history of CNV in the study eye, BCVA of 20/63 (or 59
letters) or better and no confounding ocular conditions
Interventions Intravenous eculizumab or intravenous saline
Outcomes Primary outcome: growth in GA/change in drusen volume
Starting date July 2009
Contact information Principal investigator: Philip J Rosenfeld, MD, PhD
Notes NCT00935883 is active but not recruiting, having had a final data collection date of June 2012
NCT00950638
Trial name or title ’A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry AMD’
Methods Randomised, open-label, dose comparison, parallel assignment, phase I study
Participants Over 50 years of age with dry AMD in both eyes
Interventions ARC1905 intravitreal injection (dose comparison)
Outcomes Presence of any dose-limiting toxicity; safety endpoints include adverse events, vital signs, ophthalmic variables
and outcomes
Starting date July 2009
Contact information Ophthotech Corporation, New York, USA
Notes NCT00950638 is examining the safety and tolerability of intravitreal ARC-1905 for GA secondary to AMD.
It is active but not recruiting, with a final data collection date of September 2012
AMD: age-related macular degeneration
BCVA: best corrected visual acuity
CNV: choroidal neovascularisation
GA: geographic atrophy
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Macular Degeneration
#2 MeSH descriptor Retinal Degeneration e
#3 MeSH descriptor Retinal Neovascularization
#4 MeSH descriptor Choroidal Neovascularization
#5 MeSH descriptor Macula Lutea
#6 maculopath*
#7 (macul* or retina* or choroid*) near/3 (degener*)
#8 (macul* or retina* or choroid*) near/3 (neovasc*)
#9 macula* near/2 lutea
#10 AMD or ARMD or CNV
#11 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10)
#12 MeSH descriptor Complement System Proteins
#13 (cascad* or inhibit*) near/3 (complement)




#18 (#12 OR #13 OR #14 OR #15 OR #16 OR #17)
#19 (#11 AND #18)
Appendix 2. MEDLINE (OvidSP) search strategy
1. randomized controlled trial.pt.









11. 9 not (9 and 10)
12. 8 not 11
13. exp macular degeneration/
14. exp retinal degeneration/
15. exp retinal neovascularization/
16. exp choroidal neovascularization/
17. exp macula lutea/
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18. maculopath$.tw.
19. ((macul$ or retina$ or choroid$) adj3 degener$).tw.
20. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
21. (macula$ adj2 lutea).tw.
22. (AMD or ARMD or CNV).tw.
23. or/13-22
24. exp complement system proteins/
25. (complement adj3 (cascad$ or inhibit$)).tw.





31. 23 and 30
32. 12 and 31
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville et al (Glanville 2006).
Appendix 3. EMBASE (OvidSP) search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.




18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp retina macula degeneration/
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34. exp retina degeneration/
35. exp retina neovascularization/
36. exp subretinal neovascularization/
37. maculopath$.tw.
38. ((macul$ or retina$ or choroid$) adj3 degener$).tw.
39. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
40. exp retina macula lutea/
41. (macula$ adj2 lutea$).tw.
42. (AMD or ARMD or CNV).ti,ab.
43. or/33-42
44. exp complement/
45. (complement adj3 (cascad$ or inhibit$)).tw.





51. 43 and 50
52. 32 and 51
Appendix 4. AMED (OvidSP) search strategy
1. exp eye disease/
2. exp vision disorders/
3. exp retinal disease/
4. maculopath$.tw.
5. ((macul$ or retina$ or choroid$) adj3 degenerat$).tw.
6. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
7. or/1-6
8. (complement adj3 (cascad$ or inhibit$)).tw.





14. 7 and 13
Appendix 5. LILACS search strategy
macul$ or retina$ or choroid$ and degenerat$ or neovascula$ and complement or C3 or C5 or eculizumab or compstatin or POT 4
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Appendix 6. OpenGrey search strategy
macul$ or retina$ or choroid$ AND degenerat$ or neovascula$ AND complement or C3 or C5 or eculizumab or compstatin or POT
4
Appendix 7. Web of Science CPCI-S search strategy
#4 #2 AND #3
#3 TS= (complement or C3 or C5 or eculizumab or compstatin or POT 4)
#2 TS= (degenerat* or neovasc*) AND #1
#1 TS= (macula* or retina* or choroid*)
Appendix 8. metaRegister of Controlled Trials search strategy
macula AND (complement or C3 or C5 or eculizumab or compstatin or POT 4)
Appendix 9. ClinicalTrials.gov search strategy
macula AND complement
Appendix 10. ICTRP search strategy
macula = Condition AND complement = Intervention
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